Connect with us

BIOTECH

Generex Biotechnology Corporation (OTCMKTS:GNBT) Reports A Decrease Of 9.09% In Short Interest

Published

on

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced recently that it has registered a decline of 9.09% in its short interest. Though the company doesn’t have a noteworthy business operation, it has recorded a market cap of $3.52 million.

In the past, Generex was fully engaged in research and product development and distribution of drug delivery systems and other advanced technologies for the treatment of patients with metabolic and immunological medical conditions. But with continuous negative earnings, the firm has shifted to its proprietary technology. The company currently administers formulations of huge molecule drugs to the oral cavity using its technology and a hand-held aerosol applicator.

Generex recently also issued a 2017 year-end summary of its performance to the stakeholders. Joseph Moscato, President, and CEO of the company provided his stockholders a summary of how the company has performed and highlight great achievements in 2017.

Through an official letter, Moscato stressed on what the company accomplished in last year’s fiscal year which includes: appointing more members for the company’s Board of Directors with a focus on the mix of leaders from various fields such as finance, drug development and drug delivery, product development and corporate governance; recruitment of a solid management team with necessary skills, knowledge, and expertise; implemented a shareholder-approved reverse stock split, and much more.

The company also pointed out the need to rebuild the company to be a strategic, diversified life sciences holding firm. There is also a plan to rebrand the company with a new name – NuGenerex Life Sciences Holdings, Inc before the end of this year.

The company plans to restructure the newly branded NuGenerex into three key operating subsidiaries to enhance its platform technologies especially in cancer immunotherapy, rapid diagnostic testing, and general drug formulation and delivery systems.

The three subsidiaries include NuGenerex Immuno-Oncology based on AE37; NuGenerex Global Diagnostics, and NuGenerex Drug Delivery Systems. Furthermore, the company will also launch NuGenerex Healthcare and Clinical Finance department that will focus on healthcare investment fund.

BIOTECH

Insys Therapeutics Inc (NASDAQ:INSY) Issues An Update on CBD Pharmaceuticals and Spray Technology Products

Published

on

By

Insys Therapeutics Inc (NASDAQ:INSY) has issued an update on the naloxone nasal and epinephrine sprays and CBD oral solutions. CEO and President of Insys Therapeutics, Saeed Motahari said the company is focusing on novel drug delivery systems and pharmaceutical grade cannabinoids to drive the growth going forward. It is moving away from opioids. The company is transforming its business strategy to include patient-centric formulations over the past one year. Going forward,  Insys Therapeutics is preparing to submit 6 innovative drug applications in the next 3 years. The company is scheduling two of them in 2019.

An update on the Opioid Related Assets

As per the announced plans,  Insys Therapeutics is scheduling the alternative review of the opioid related assets. As of now, nine firms have entered into a pact with  Insys Therapeutics and are reviewing the confidential information. The company will release an update on this aspect in early 2019.

An Update on the Lifesaving Products

Insys Therapeutics is in the advanced stages of developing the lifesaving investigational products that are based on spray technologies. Its lifesaving products in development include epinephrine nasal spray for anaphylaxis and naloxone nasal spray for the opioid overdose.

The company is also focusing on cannabinoids like CBD oral solution targeting the child absence epilepsy treatment (phase 2), Prader Willi Syndrome (phase 2), infantile spasms (phase 3), and dronabinol inhalation to treat a variety of conditions such as anorexia in patients suffering from cancer.

Insys Therapeutics is conducting a non-clinical toxicity study on naloxone nasal spray and expects to announce the results in March 2019. The company has set the timeframe for the NDA submission in Q1 2019.

Epinephrine nasal spray, which is intended for needle-free delivery, is a substitute to the intramuscular injection. According to the study, it is readily absorbed via the nasal mucosa. The company has obtained FDA nod for fast track designation for the drug in August 2018. It has also provided specific guidelines for filing requirement and clinical development. Insys Therapeutics is optimistic to complete the filing requirements for epinephrine NDA in Q4, 2019. It is subject to successful completion of PK study.

The company has successfully completed a proof of concept study on dronabinol inhalation in September 2018. Insys Therapeutics will arrange a meeting with clinical experts in Q1 2019 to discuss further development for this investigational formulation.

Insys Therapeutics Signs a Pact with Lunatus for Commercializing SUBSYS

Insys Therapeutics has signed a definitive accord with Lunatus for commercializing Subsys in 8 nations in the Middle East. Following the deal, Lunatus will act as an authorized agent and licensee in the UAE, Lebanon, Kuwait, Jordan, Saudi Arabia, Qatar, Oman, and Bahrain.

Continue Reading

BIOTECH

International Consolidated Inc (OTCMKTS:INCC) Pronounces A $5 Million Dollar Institutional Offer

Published

on

International Consolidated Inc (OTCMKTS:INCC) is quite pleased to make the announcement that obtained an institutional offer worth $5 million dollars from the IFG Opportunity Fund LLC. According to a person well conversant with the matter, it happened prior to the company becoming fully reporting.

The business guru is making plans to move ahead and execute its business plan and it is crucial to mention the point that the undertaking served them with about three 3 additional options for funding.

The company’s take on business operations

It was way back in 2004 that the IFG Opportunity Fund, LLC began as a private equity fund set up to make investments in the series of the small growth companies via the PIPE’s which are fundamentally private investments in public equities.

They invest in their own capital and that of course indicates more flexibility as well as a greater competitive advantage at a time when business dynamics tend to be shifting quite fast. Competitive pricing is a point that the business giant takes with much seriousness and market observers have termed that a great way to move about business.

The water-soluble CBD oil super food and expert strategies

The water-soluble CBD oil super food and wellness drinks that are being introduced by BluDog Products are easily absorbed. And they are the perfect alternative for over-the-counter therapeutic option that helps promote well being and relaxation.

Asides from that they play a significant role helping relieve post-sports inflammation not forgetting that the CBD products naturally interact with the anti-inflammatory system of the body and there are no associated side effects.

The Managing Member of BluDog Products LLC Antonio Uccello while moving out of a business conference addressed news reporters telling them that as a company they were quite pleased about getting to the point of providing high quality BluDog Products.

Much has been happening in the recent years, one of the things being the acquisition of the American Nutritional Products Inc. Several market analysts have said that the company is placing itself on the right path in the quest to achieve monumental success in a market characterized with stiff competition.

Continue Reading

BIOTECH

Premier Biomedical Inc (OTCMKTS:BIEI) Searches For Development Partner To Develop Patent Pending Technology

Published

on

Premier Biomedical Inc (OTCMKTS:BIEI) reported that they are actively looking for an associate to advance their patented extracorporeal treatment procedure in together with their patent pending process for treating ailments through the application of lasers.

The buzz

The methodology uses the concept of curing the blood outside the human body in a continuous flow procedure, together with an emissive energy means, such as a laser, to destroy directed antigens in the blood, before returning the blood to the person. The firm has exceptional privileges to three dispensed patents, one provisional patent application and six pending applications, all related to unique treatments for cancer as well as extracorporeal treatments for different life-threatening ailments.

Dr. Felder, the Inventor of the underlying technologies, expressed that the application of lasers in conjunction with their extracorporeal treatment procedure is a thrilling concept, as it should eliminate any infectious ailment, without the probability of pathogen resistance, or the action of side effects from the therapy. It also has the prospect for being an efficacious and inexpensive treatment for septicemia — a major cause of death globally.

William A. Hartman, the CEO and President of Premier Biomedical, expressed that they consider this combination of their patented extracorporeal treatment procedure with their patent awaiting emissive energy ablation of directed antigens could pave a complete new chapter in the means diseases are cured. The efficacy and safety of treatment protocols for a broad range of ailments could be considerably improved.

Premier Biomedical marks as a research-based publicly traded firm that plans to develop and discover medical treatments for a broad range of ailments in humans. The company has obtained, through different license agreements, the know-how behind three allowed US Patents, several pending provisional patents, as well as a ‘PCT’ Europe National Patent. Premier Biomedical was established back in 2010.

Continue Reading
Advertisement
Advertisement

TRENDING STORIES

INDUSTRIAL HEMP2 months ago

Digipath Inc. (OTCMKTS: DIGP) Announce Significant Milestones On Development Of GroSciences Hemp-Test Kit

Post Views: 328 Digipath Inc. (OTCMKTS:DIGP) has announced that its GroSciences subsidiary has made substantial progress in the development of...

INDUSTRIAL HEMP2 months ago

Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Launches Expands Its Footprint In Florida With New Medical Marijuana dispensary in Gainesville

Post Views: 361 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) recently announced that it launched a new outlet in Gainesville, making...

INDUSTRIAL HEMP2 months ago

Harvest Health & Recreation Inc (OTCMKTS:HRVSF) Gets Greenlight To Expand Its Foreign Private ISSUER Threshold

Post Views: 331 Harvest Health & Recreation Inc (OTCMKTS:HRVSF) revealed earlier this month that its Board of Directors has approved...

INDUSTRIAL HEMP2 months ago

Generex Biotechnology Corporation (OTCMKTS:GNBT) Adds MediSource Partners And Pantheon Medical To Its NuGenerex Family Of Subsidiaries

Post Views: 289 Generex biotechnology Corporation (OTCMKTS:GNBT) has welcomed MediSource Partners to its family of subsidiaries and introduced Pantheon Medical...

INDUSTRIAL HEMP2 months ago

CBD Unlimited Inc. (OTCMKTS:EDXC) Enhances Its Convenience Store Program Targeting 300 Stores

Post Views: 278 CBD Unlimited Inc. (OTCMKTS:EDXC), formerly Endexx Corporation, has announced an enhanced convenient store launch program. The provider...

INDUSTRIAL HEMP2 months ago

Cronos Group Inc. (NASDAQ:CRON) Spends $300 Million On CBD Skincare Businesses

Post Views: 264 Cronos Group Inc. (NASDAQ:CRON) has not had the best of runs in recent months, after starting the...

INDUSTRIAL HEMP2 months ago

Elev8 Brands, Inc. (OTCMKTS:VATE) A Potential Break Out Play On Sales Growth Boost

Post Views: 279 Elev8 Brands, Inc. (OTCMKTS:VATE) stock is a potential break out play as a flurry of positive developments...

INDUSTRIAL HEMP2 months ago

Medical Marijuana Inc. (OTCMKTS:MJNA) Eyes Fresh Gains On Improving Fundamentals

Post Views: 175 Medical Marijuana Inc. (OTCMKTS:MJNA) bounce back from all-time lows continues to gather pace on improving fundamentals. Investor’s...

INDUSTRIAL HEMP2 months ago

Sugarmade Inc. (OTCMKTS:SGMD) Turns To Hemp Production To Reinvigorate Growth Prospects

Post Views: 181 Sugarmade Inc. (OTCMKTS:SGMD) has made a strategic investment in Hempistry as it tries to reinvigorate its growth...

INDUSTRIAL HEMP9 months ago

Auxly Cannabis Group Inc (OTCMKTS:CBWTF) Acquires 46% Stake In Curative Cannabis And Agrees to Fund Cannabis Cultivation Facility To Produce Ultra Premium Cannabis

Post Views: 181 Auxly Cannabis Group Inc (OTCMKTS:CBWTF) has entered a deal to take over a 46% stake in Curative...

Advertisement

Whats Hot

CULTIVATING

SHAREHOLDER VALUE

 

Trading Symbol

CSE: CHOO
OTCQB: CHOOF

Choom Holdings Inc. CSE: CHOO | OTCQB: CHOOF